Top stories
Sanofi and Genzyme have presented additional data analysis demonstrating Lemtrada's superiority over Rebif in reducing disability in MS. However, due to Lemtrada's potential to lead to the development of autoimmune adverse events, Datamonitor expects that the drug will be used at later lines of therapy and in patients with severe forms of MS...more >>
Strong Q1 sales and significant velocity for its ADHD product Vyvanse suggest that Shire will be heralding a new blockbuster by the end of the year. Furthermore, with approval pending in European markets and investigations into additional psychiatric indications providing promising results, Vyvanse is set to deliver long-term sales growth...more >>
Eisai's insomnia drug Lunesta is now available in Japan and will be well received on account of its efficacy in terms of both sleep onset and sleep maintenance. An identical pricing strategy to the current market leader, Sanofi's and Astellas's Myslee, suggests that Eisai has ambitious plans for Lunesta and has already identified its major competitor...more >>
Safety concerns and high price points have limited the use of Novartis's Gilenya in the European multiple sclerosis market since its launch in January 2011. However, the decision by the UK's cost watchdog to recommend Gilenya for multiple sclerosis will support the product's future sales, which Datamonitor estimates will reach $2.2bn across the seven major markets by 2020...more >>